Boxed Warning: USFDA issues most serious warning on menopause medicine Ruchika Sharma18 Dec 2024 11:30 AM ISTUS Food and Drug Administration (USFDA) has added a boxed Warning highlighting the known risk of rare but serious liver injury associated with use of...
Fezolinetant therapy effective for women with menopausal vasomotor symptoms: Study Jacinthlyn Sylvia2 July 2024 8:00 PM ISTA recent study published in the Menopause journal found promising outcomes for women who undergo moderate-to-severe vasomotor symptoms (VMS) due to...
Menopause drug fezolinetant safely reduces hot flushes for almost 6 months, reveals research Dr. Kamal Kant Kohli17 May 2024 8:00 PM ISTFezolinetant reduces the frequency and severity of hot flushes during menopause for 24 weeks, without serious side effects, according to research...
Fezolinetant Shows Promise in Alleviating Menopausal Vasomotor Symptoms Dr Riya Dave4 March 2024 9:00 PM ISTMenopausal vasomotor symptoms (VMS), including hot flashes and night sweats, can significantly impact the quality of life of women transitioning...
FDA Approves first oral non hormonal treatment for Moderate to Severe Hot Flashes Caused by Menopause Dr. Kamal Kant Kohli13 May 2023 11:15 AM ISTThe US Food and Drug administration has approved fezolinetant (Veozah) for treatment of moderate to severe hot flashes caused by menopause....
Fezolinetant effective treatment of vasomotor symptoms associated with menopause Jacinthlyn Sylvia6 March 2023 11:00 AM ISTA study by Kimball A Johnson and peers found fezolinetant to be a safe and effective treatment for moderate-to-severe vasomotor symptoms (VMS)...
Fezolinetant safe and effective treatment for VMS associated with menopause: Phase 3 SKYLIGHT trial Dr. Kamal Kant Kohli19 Oct 2022 12:15 PM ISTUSA: According to data presented at the NAMS Annual Meeting, women using fezolinetant for moderate to severe vasomotor symptoms experienced a...
Fezolinetant reduces frequency and severity of menopausal hot flashes, finds Phase 3 study Dr. Kamal Kant Kohli24 Jun 2022 11:00 AM ISTATLANTA: Fezolinetant significantly reduced the frequency and severity of moderate-to-severe vasomotor symptoms (VMS), or hot flashes, associated with...
